US news The controversial ketamine-like drug that Trump is pushing on veterans


US president Donald Trump has reportedly expressed his enthusiasm for the new fast acting anti-depressant nasal spray derived from ketamine, known as esketamine, and has put the provocative drug on a fast track at the Department of Veterans Affairs (VA).

The new “miracle drug” was given FDA approval back in March after a joint FDA advisory committee voted 14-2 to approve the drug for release.

The drug esketamine provides “a quick molecular reset button for brains impaired by stress or depression.” Initially developed as an intravenous drug, Johnson & Johnson (J&J) has developed a nasal solution called Spravato that has the same effect. The various analysis of the drug estimate that Spravato could earn $600 million for the company by 2022.

Via: Mixmag


Comments

Send this to a friend